Thallion, LFB Cement Shigamabs Deal

February 2010
Bioworld Week;2/22/2010, Vol. 18 Issue 8, p3
The article announces the availability of the funding for the Thallion Pharmaceuticals Inc. in Montreal, Quebec to move its Phase II E. Coli treatment all the way through commercialization.


Related Articles

  • Clinic Roundup.  // BioWorld Today;10/13/2011, Vol. 22 Issue 199, p5 

    This section offers news briefs on clinical trials including the first patient treated by Intellikine Inc. in a Phase I study of INKN1117 and the resumption of patient enrollment by Thallion Pharmaceuticals Inc. for its Phase II trial of Shigamabs in Shigatoxin-producing Escherichia coli.

  • Taro Pharma arm to buy Canada’s Thallion Pharma.  // FRPT- Chemical Snapshot;4/4/2017, p2 

    The article offers information on acquisition of Thallion Pharmaceuticals by Taro Pharmaceuticals, indirect arm of Sun Pharmaceutical Industries to expand product development and mentions rights for development of orphan drug candidate Shigamab targeting E. Coli-induced haemolytic uremic syndrome.

  • Past Funding Woes, Thallion Gets Cash, E. Coli Drug Partner. Hollingsworth, Catherine // BioWorld International;12/23/2009, Vol. 14 Issue 51, p4 

    The article reveals that Montreal, Quebec-based Thallion Pharmaceuticals Inc. sold its Caprion Proteomics Inc. subordinated promissory note back to Caprion for an immediate cash payment and have partnered with French firm LFB Biotechnologies to develop Shigamabs, monoclonal antibodies designed...

  • CLINIC ROUNDUP.  // BioWorld Today;9/29/2008, Vol. 19 Issue 189, p2 

    This section offers news briefs on the pharmaceutical industry in North America. A Phase I study has been completed by Memory Pharmaceuticals Corp. involving its R4996/MEM 63908. Meanwhile, Thallion Pharmaceuticals Inc. has enrolled the first patient in its Phase II trial of TLN-4601 as a...

  • With FDA Talks Stalled, Thallion Looks Abroad. Morrison, Trista // BioWorld Today;10/30/2007, Vol. 18 Issue 211, p1 

    The article reports that Thallion Pharmaceuticals Inc. has been looking to continue a program for Shigamabs outside of the U.S., in October 2007. The move followed after the company failed to reach an agreement with the U.S. Food and Drug Administration. Shigamabs is used in the treatment of...

  • Other News To Note.  // BioWorld Today;7/11/2013, Vol. 24 Issue 131, p2 

    This section offers news briefs on the biotechnology industry as of July 2013. Healthcare company Bellus Health Inc. and Thallion Pharmaceutical Inc. has amended their acquisition agreement on June 17, 2013, pertaining to the proposed acquisition of Thallion by Bellus. Biopharmaceutical firm...

  • FINANCINGS ROUNDUP.  // BioWorld Today;6/4/2009, Vol. 20 Issue 106, p4 

    This section offers news briefs related to the financial status of pharmaceutical companies. Biovail Corp. announced that it will provide up to $200 million aggregate principal amount of its senior convertible notes in a private offering to qualified institutional buyers. Thallion...

  • CLINIC ROUNDUP.  // BioWorld Today;11/19/2007, Vol. 18 Issue 225, p7 

    This section offers news briefs on the biotechnology industry. Paris, France-based BioAlliance Pharma SA has enrolled patients in a Phase III trial for Loramyc for the treatment of oropharyngeal candidiasis. Montreal-based Thallion Pharmaceuticals Inc. presented positive safety and efficacy data...

  • CLINIC ROUNDUP.  // BioWorld Today;2/7/2008, Vol. 19 Issue 26, p5 

    This section offers news briefs related to the pharmaceutical industry. Hasbrouck Heights, New Jersey-based Nymox Pharmaceutical Corp. said an analysis of results from its new multi-center Phase II study of NX-1207 for benign prostatic hyperplasia (BPH) showed statistically significant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics